Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
March 09 2017 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it
will host a conference call and live webcast to discuss its 2016
fourth quarter and year end financial results and provide a
corporate update on Wednesday, March 15, 2017 at 4:30 p.m. ET.
A live and archived version of the audio
presentation will be available online at
http://www.investorcalendar.com/IC/CEPage.asp?ID=175658 as well as
through the "Webcast" tab on Inovio's home page at www.inovio.com.
This is a listen-only event but will include a live Q&A with
analysts.
A replay of the conference call will be
accessible two hours after the call at 877-481-4010 (domestic) or
919-882-2331 (international) using passcode 10254.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, ApolloBio
Corporation, Drexel University, NIH, HIV Vaccines Trial Network,
National Cancer Institute, U.S. Military HIV Research Program, and
Laval University. For more information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs, the availability of funding to support
continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or
develop viable DNA vaccines, our ability to support our broad
pipeline of SynCon® active immunotherapy and vaccine products, the
ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will
enable us to receive future payments and royalties, the adequacy of
our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted
by the company or its collaborators, including alternatives that
may be more efficacious or cost effective than any therapy or
treatment that the company and its collaborators hope to develop,
issues involving product liability, issues involving patents and
whether they or licenses to them will provide the company with
meaningful protection from others using the covered technologies,
whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand
claims of invalidity and whether the company can finance or devote
other significant resources that may be necessary to prosecute,
protect or defend them, the level of corporate expenditures,
assessments of the company's technology by potential corporate or
other partners or collaborators, capital market conditions, the
impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended December
31, 2015, our Form 10-Q for the quarter ended September 30,
2016, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024